Oral Lamivudine for Extended HIV Postnatal Prophylaxis. [PDF]
Van de Perre P +8 more
europepmc +1 more source
Resensitizing the Untreatable: Zidovudine and Polymyxin Combinations to Combat Pan-Drug-Resistant <i>Klebsiella pneumoniae</i>. [PDF]
Kaur JN +12 more
europepmc +1 more source
Hyperlipidemia and associated risk factors among people living with HIV on antiretroviral therapy: a retrospective cohort study from Eastern China. [PDF]
Cheng W +6 more
europepmc +1 more source
Optimizing Identification and Care of Pregnant/Breastfeeding Women Living With HIV in Resource-Limited Settings. [PDF]
Fowler MG, Chou VB, Musoke P.
europepmc +1 more source
HIV-1 Resistance to Dolutegravir in Benin: The Need to Improve and Strengthen Therapeutic Patient Education Strategies to Achieve the Third Objective 95 of UNAIDS 95-95-95 Target. [PDF]
Tchiakpe E +4 more
europepmc +1 more source
Clinical and biological risk factors influencing infant HIV status: a case study of Kisenyi Health Center IV, Kampala, Uganda. [PDF]
Bagonza FX +3 more
europepmc +1 more source
Incidence and correlates of chronic anemia in people living with HIV Initiating ART: An exploratory five-year retrospective cohort of patients retained in care. [PDF]
Kamvuma K +5 more
europepmc +1 more source
Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial. [PDF]
Obeng BM +22 more
europepmc +1 more source
Combined tenofovir, lamivudine, and dolutegravir treatment increases leptin and FABP4 expression in human subcutaneous adipose tissue. [PDF]
Zanardo LW +8 more
europepmc +1 more source
Cytopenias With HIV in the Era of Highly Active Antiretroviral Therapy: Are We Winning the Battle? [PDF]
Obeagu EI.
europepmc +1 more source

